SANUWAVE Health, Inc. (SNWV)
| Market Cap | 65.61M -74.6% |
| Revenue (ttm) | 44.34M +22.5% |
| Net Income | 16.49M |
| EPS | 0.92 |
| Shares Out | 8.60M |
| PE Ratio | 8.27 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 201,985 |
| Open | 8.61 |
| Previous Close | 8.57 |
| Day's Range | 7.53 - 8.68 |
| 52-Week Range | 7.53 - 46.59 |
| Beta | 1.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
Financial StatementsNews
SANUWAVE Health Transcript: Planet MicroCap Las Vegas 2026
Wound care is undergoing a payer-driven shift to evidence-based medicine, creating opportunities for high-efficacy, cost-effective solutions. UltraMIST’s strong clinical evidence, expanding reimbursement, and consumables-driven model position it for growth, especially as it targets large enterprise accounts.
Sanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16,...
SANUWAVE Health Slides: Investor presentation
SANUWAVE Health has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
SANUWAVE Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation votes. Quorum was met, voting was conducted online, and results will be disclosed in a Form 8-K. Only meeting-related questions were addressed during the Q&A.
SANUWAVE Health Earnings Call Transcript: Q1 2026
Record Q1 revenue and strong consumables growth were achieved despite a market freeze from CMS pricing changes. Guidance for 2026 remains robust, with expectations for a stronger second half driven by seasonality and large account engagement.
SANUWAVE Health Quarterly report: Q1 2026
SANUWAVE Health has published its Q1 2026 quarterly earnings report on May 13, 2026.
SANUWAVE Health Earnings release: Q1 2026
SANUWAVE Health released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
SANUWAVE Health Slides: Q1 2026
SANUWAVE Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Sanuwave Health reports Q1 EPS (17c) vs (72c) last year
Reports Q1 revenue $9.6M vs $9.3M last year. “The seemingly ubiquitous question in advanced wound care during Q1 was ‘When is the turn coming and when will the recovery start?’”…
Sanuwave Health sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
17:03 EDT Sanuwave Health (SNWV) sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
Sanuwave Health backs FY26 revenue view $51M-$55M, one estimate $51.35M
17:03 EDT Sanuwave Health (SNWV) backs FY26 revenue view $51M-$55M, one estimate $51.35M
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Sanuwave Health narrows Q1 revenue view to $9.6M-$9.7M from $9.6M-$10.3M
Q1 revenue consensus $9.84M. “At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in…
Sanuwave Health price target lowered to $47 from $53 at Roth Capital
Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue…
SANUWAVE Health Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue growth driven by UltraMIST system sales and consumables, despite industry disruption from CMS reimbursement changes. Strategic channel shift to resellers and strong cash position support 2026 growth outlook of 16%–25%.
SANUWAVE Health Earnings release: Q4 2025
SANUWAVE Health released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
SANUWAVE Health Annual report: Q4 2025
SANUWAVE Health has published its Q4 2025 annual report on March 27, 2026.
SANUWAVE Health Slides: Q4 2025
SANUWAVE Health has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 27, 2026.
Sanuwave Health reports Q4 adjusted EBITDA $4.77M vs $3.66M last year
Reports Q4 revenue $13.4M, up 29.7% year-over-year. “We’re pleased to be, once more, announcing an all-time record quarter for Sanuwave on both revenues and adjusted EBITDA, especially during such cha...
Sanuwave Health sees Q1 revenue $9.6M-$10.3M
17:02 EDT Sanuwave Health (SNWV) sees Q1 revenue $9.6M-$10.3M
Sanuwave Health sees FY26 revenue $51M-$55M
17:03 EDT Sanuwave Health (SNWV) sees FY26 revenue $51M-$55M
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.